Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.
You may also be interested in...
As Korea Pharmas Look To U.S., U.S. VC Looks To Korea
NEW YORK - Oxford Bioscience Partners has chosen Korea as its first Asian country to invest in via a partnership with Hanwha Venture Capital in Seoul
FDA's FOBs Implementation Begins With Meetings Both Public And Private
Agency will seek open stakeholder input on pathway development, but sponsors are also making some headway in getting individual consultations.
FDA's FOBs Implementation Begins With Meetings Both Public And Private
Agency will seek open stakeholder input on pathway development, but sponsors are also making some headway in getting individual consultations.